m-Health用于免疫接种后不良事件检测的效果:STARSS随机对照试验
STARSS多中心随机对照试验评估短信(SMS)用于免疫接种后不良事件(AEFI)监测的效果与可接受性。研究纳入6338名参与者,随机分为SMS组或对照组,SMS组在接种后第2、7、14天发送提示。结果显示SMS组AEFI检测率为4.3%,对照组为0.3%,SMS组检测率提高13倍。
要点
- SMS主动监测可显著提高AEFI检测率,较被动监测提高13倍。
- SMS组184例 verified AEFI,对照组仅6例报告AEFI。
- SMS提示应答率较高,仅9.8%未响应,90%应答者无医学事件。
核心结论
- STARSS方法可改善AEFI检测,支持更广泛使用基于SMS的监测系统。
研究设计与样本
- 多中心随机对照试验,纳入6338名成人接种者或儿童家长,随机分为两个SMS组或对照组。
主要发现
- SMS组(4225人)收到12675条监测提示,9.8%未响应;应答者中90%无医学事件,184例 verified AEFI。
- 对照组6例报告AEFI,SMS组AEFI检测率为4.3%,对照组为0.3%,SMS组检测率提高13倍。
临床怎么用
- 在疫苗接种后采用SMS主动提示(第2、7、14天)可提高AEFI监测灵敏度,适用于建立稳健的药物警戒系统。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Passive surveillance is recommended globally for the detection of adverse events following immunisation (AEFI) but this has significant challenges. Use of Mobile health for vaccine safety surveillance enables a consumer-centred approach to reporting. The Stimulated Telephone Assisted Rapid Safety Surveillance (STARSS) a randomised control trial (RCT) sought to evaluate the efficacy and acceptability of SMS for AEFI surveillance. METHODS: Multi-centre RCT, participants were adult vaccinees or parents of children receiving any vaccine at a trial site. At enrolment randomisation occurred to one of two SMS groups or a control group. Prompts on days 2, 7 and 14 post-immunisation, were sent to the SMS group, to ascertain if a medical event following immunisation (MEFI) had occurred. No SMS's were sent to the control participants. Those in the SMS who notified an MEFI were pre-randomised to complete a computer assisted telephone interview or a web based report to determine if an AEFI had occurred whilst an AEFI in the controls was determined by a search for passive reports. The primary outcome was the AEFI detection rate in the SMS group compared to controls. RESULTS: We enrolled 6,338 participants, who were equally distributed across groups and who received 11,675 vaccines. The SMS group (4,225) received 12,675 surveillance prompts with 9.8% being non-compliant and not responding. In those that responded 90% indicated that no MEFI had been experienced and 184 had a verified AEFI. 6 control subjects had a reported AEFI. The AEFI detection rate was 13 fold greater in the SMS group when compared with controls (4.3 vs 0.3%). CONCLUSION: We have demonstrated that the STARSS methodology improves AEFI detection. Our findings should inform the wider use of SMS-based surveillance which is particularly relevant since establishing robust and novel pharmacovigilance systems is critical to monitoring novel vaccines which includes potential COVID vaccines.
引用
- Gold MS, Lincoln G, Cashman P, et al. Efficacy of m-Health for the detection of adverse events following immunization - The stimulated telephone assisted rapid safety surveillance (STARSS) randomised control trial. Vaccine. 2020. PMID: 33279317. doi:10.1016/j.vaccine.2020.11.056
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。